| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 19:21:52 UTC |
|---|
| Update Date | 2021-09-26 23:14:51 UTC |
|---|
| HMDB ID | HMDB0258148 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide |
|---|
| Description | N-[5-hydroxy-3-(prop-2-en-1-yldisulfanyl)pent-2-en-2-yl]-N-[(6-imino-2-methyl-1,6-dihydropyrimidin-5-yl)methyl]formamide belongs to the class of organic compounds known as aminopyrimidines and derivatives. These are organic compounds containing an amino group attached to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. Based on a literature review very few articles have been published on N-[5-hydroxy-3-(prop-2-en-1-yldisulfanyl)pent-2-en-2-yl]-N-[(6-imino-2-methyl-1,6-dihydropyrimidin-5-yl)methyl]formamide. This compound has been identified in human blood as reported by (PMID: 31557052 ). N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CC(N(CC1=CN=C(C)N=C1N)C=O)=C(CCO)SSCC=C InChI=1S/C15H22N4O2S2/c1-4-7-22-23-14(5-6-20)11(2)19(10-21)9-13-8-17-12(3)18-15(13)16/h4,8,10,20H,1,5-7,9H2,2-3H3,(H2,16,17,18) |
|---|
| Synonyms | | Value | Source |
|---|
| N-[5-Hydroxy-3-(prop-2-en-1-yldisulphanyl)pent-2-en-2-yl]-N-[(6-imino-2-methyl-1,6-dihydropyrimidin-5-yl)methyl]formamide | Generator | | Allithiamine hydrochloride | MeSH |
|
|---|
| Chemical Formula | C15H22N4O2S2 |
|---|
| Average Molecular Weight | 354.49 |
|---|
| Monoisotopic Molecular Weight | 354.118418312 |
|---|
| IUPAC Name | N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-en-1-yldisulfanyl)pent-2-en-2-yl]formamide |
|---|
| Traditional Name | N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-en-1-yldisulfanyl)pent-2-en-2-yl]formamide |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC(N(CC1=CN=C(C)N=C1N)C=O)=C(CCO)SSCC=C |
|---|
| InChI Identifier | InChI=1S/C15H22N4O2S2/c1-4-7-22-23-14(5-6-20)11(2)19(10-21)9-13-8-17-12(3)18-15(13)16/h4,8,10,20H,1,5-7,9H2,2-3H3,(H2,16,17,18) |
|---|
| InChI Key | WNCAVNGLACHSRZ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as aminopyrimidines and derivatives. These are organic compounds containing an amino group attached to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazines |
|---|
| Sub Class | Pyrimidines and pyrimidine derivatives |
|---|
| Direct Parent | Aminopyrimidines and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Aminopyrimidine
- Primary aromatic amine
- Imidolactam
- Tertiary carboxylic acid amide
- Heteroaromatic compound
- Amino acid or derivatives
- Carboxamide group
- Organic disulfide
- Allyl sulfur compound
- Sulfenyl compound
- Azacycle
- Carboxylic acid derivative
- Hydrocarbon derivative
- Primary amine
- Primary alcohol
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Alcohol
- Organic oxygen compound
- Amine
- Carbonyl group
- Organic oxide
- Organopnictogen compound
- Organic nitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross Sections| Predictor | Adduct Type | CCS Value (Å2) | Reference |
|---|
| DeepCCS | [M+H]+ | 172.872 | 30932474 | | DeepCCS | [M-H]- | 170.514 | 30932474 | | DeepCCS | [M-2H]- | 203.424 | 30932474 | | DeepCCS | [M+Na]+ | 178.965 | 30932474 |
Predicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.46 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.5982 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.05 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 986.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 187.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 108.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 148.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 62.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 296.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 328.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 394.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 755.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 245.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1080.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 248.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 264.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 334.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 267.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 142.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N[Si](C)(C)C | 3154.3 | Semi standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N[Si](C)(C)C | 2829.3 | Standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N[Si](C)(C)C | 4293.1 | Standard polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TMS,isomer #2 | C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C)[Si](C)(C)C | 3052.8 | Semi standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TMS,isomer #2 | C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C)[Si](C)(C)C | 2862.2 | Standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TMS,isomer #2 | C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C)[Si](C)(C)C | 4201.2 | Standard polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,3TMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C)[Si](C)(C)C | 3059.8 | Semi standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,3TMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C)[Si](C)(C)C | 2865.3 | Standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,3TMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C)[Si](C)(C)C | 3880.6 | Standard polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TBDMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C(C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N[Si](C)(C)C(C)(C)C | 3482.9 | Semi standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TBDMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C(C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N[Si](C)(C)C(C)(C)C | 3233.8 | Standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TBDMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C(C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N[Si](C)(C)C(C)(C)C | 4300.3 | Standard polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TBDMS,isomer #2 | C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3433.2 | Semi standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TBDMS,isomer #2 | C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3279.8 | Standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,2TBDMS,isomer #2 | C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4192.0 | Standard polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,3TBDMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C(C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3584.2 | Semi standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,3TBDMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C(C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3445.2 | Standard non polar | 33892256 | | N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-N-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide,3TBDMS,isomer #1 | C=CCSSC(CCO[Si](C)(C)C(C)(C)C)=C(C)N(C=O)CC1=CN=C(C)N=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3969.2 | Standard polar | 33892256 |
|
|---|